Latest Pre-exposure prophylaxis Stories
WASHINGTON, Dec. 23, 2010 /PRNewswire-USNewswire/ -- On December 17, Science Magazine recognized a promising HIV study as one of the top ten achievements of 2010.
SEATTLE, Dec. 1, 2010 /PRNewswire-USNewswire/ -- World AIDS Day 2010 comes at a time of renewed hope in the HIV prevention field. In the past 15 months, scientific research has delivered exciting results in the fight against HIV.
CONRAD is pleased to join in congratulating the Global iPrEx study team for their successful trial of oral tenofovir (TDF) with emtricitabine (FTC) for HIV prevention.
In a finding with the potential to fundamentally change strategies to slow the global HIV epidemic, a new study called iPrEx shows that individuals at high risk for HIV infection who took a single daily tablet containing two widely used HIV medications, emtricitabine and tenofovir (FTC/TDF), experienced an average of 43.8% fewer HIV infections than those who received a placebo pill (95% CI 15.4 to 62.6%; P=0.005).
NIH's NIAID-sponsored Study Finds Pre-exposure Prophylaxis Concept Effective Among Men who Have Sex with Men A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men. The findings, a major advance in HIV prevention research, come from a large international clinical trial published online Nov. 23 by the New England Journal of Medicine. The study, titled "Chemoprophylaxis...
The results of the iPrEx PrEP effectiveness trial of once-daily TDF/FTC (brand name Truvada) in gay men, transgender women and other men who have sex with men are a landmark in HIV prevention research.
In a significant advance for HIV prevention research, a clinical trial confirms that the same drugs used for treating HIV can also help prevent HIV infection in the first place.
Results of the world's first efficacy trial of an HIV-prevention approach called oral pre-exposure prophylaxis, or PrEP, were released online in the New England Journal of Medicine today.
Public health agencies and communities must move quickly to translate trial results into impact NEW YORK, Nov. 23, 2010 /PRNewswire-USNewswire/ -- "This is a great day in the fight against AIDS.
SEATTLE, Nov. 23, 2010 /PRNewswire/ -- Congratulations to the investigators and staff who conducted iPrEx, a rigorous trial of HIV prevention by administration of daily anti-retroviral medicine to men at high risk of HIV infection.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.